What A Whiz! Takeda Spins Off Discovery Op Axcelead Into New Fund
Takeda has spun off into a new joint investment fund selected drug discovery operations in Japan that had been shifted to the new Axcelead business last year, further honing its focus ahead of the Shire acquisition and in a move to foster a more effective early-stage ecosystem in the country.
You may also be interested in...
Takeda continues to pursue the transformation of its R&D activities, which has already led to expansion of the pipeline, but will continue with core strategies including partnering even after the huge Shire acquisition.
After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.
In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to Scrip on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.